SME Times is powered by   
Search News
Just in:   • SpiceJet re-introduces 'Zero Change fee' offer  • 'Good' progress made at nuclear talks but issues remain: Iran  • Fiscal package may be on cards to maintain economic recovery amid Covid 2.0  • Striking taxi drivers demands unreasonable: Goa tourism body  • Govt notifies Rs 6k cr PLI scheme for AC, LED light manufacturing 
Last updated: 08 Nov, 2017  

GlaxoSmithkline.9.Thmb.jpg GlaxoSmithkline Healthcare net up 4.3 pc in Q2

   Top Stories
» Fiscal package may be on cards to maintain economic recovery amid Covid 2.0
» FICCI writes to 25 CMs on Covid management
» Regulation of insolvent firms' shares still remains a dilemma
» ECLGS 2.0 now covers SMA-1 borrowers
» Forex reserves up by over $4 bn
SME Times News Bureau | 08 Nov, 2017
GlaxoSmithkline Consumer Healthcare Ltd on Tuesday reported a Rs 192-crore net profit for the second quarter (Q2) of fiscal 2017-18, registering a marginal 4.3 per cent annual growth from Rs 184 crore in the same period last year.

Sequentially, however, the net profit for Q2 is 46 per cent up from Rs 132 crore posted in the last quarter.

In a regulatory filing on the BSE, the NCR-based company said the revenue from operations at Rs 1,115 crore for Q2 was 6.5 per cent annually lower than Rs 1,193 crore in the like period of last year but up 6.6 per cent sequentially from Rs 1,046 crore in the last quarter.

The blue chip company's scrip of Rs 10 face value lost Rs 43 per share in Tuesday's trading on the BSE to end at Rs 5,466.05 from Monday's closing rate of Rs 5,509.65 and opening price of Rs 5,549.95.
Print the Page Add to Favorite
Share this on :

Please comment on this story:
Subject :
(Maximum 1500 characters)  Characters left 1500
Your name:

  Customs Exchange Rates
Currency Import Export
US Dollar
UK Pound
Japanese Yen 58.85 56.85
As on 18 Apr, 2021
  Daily Poll
COVID-19 has directly affected your business
 Can't say
  Commented Stories
» Covid second wave: Lockdown or no lockdown(2)
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter